# Verastem Oncology Names Michael Bailey as CEO, Prices $250 Million Offering

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/31698
Published: 2026-10-14T10:17:24.000Z
Updated: 2026-10-14T10:17:24.000Z
Section: Business

> Shares climbed around 20% in premarket trading Wednesday, Oct. 14. Bailey’s appointment takes effect Jan. 1, 2027.

Verastem Oncology named Michael Bailey as its next president and CEO and priced a stock offering expected to raise $250 million, while its shares climbed around 20% in premarket trading Wednesday, Oct. 14.

Bailey is scheduled to take both roles effective Jan. 1, 2027.